Chronic Hepatitis B Market - A Global and Regional Analysis: Focus on Regional Analysis - Analysis and Forecast, 2025-2035
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
This report will be delivered in 7-10 working days.Market Lifecycle Stage
The global chronic hepatitis B market is currently in the growth stage, driven by significant advancements in the diagnosis and treatment of the disease. The market is evolving as new therapeutic options, such as gene-editing technologies and immune modulation therapies, move closer to regulatory approval. As clinical trials for these advanced therapies progress, they present an opportunity for market expansion and disruption. These emerging therapies are expected to drive the growth of the market. However, challenges such as high treatment costs and the need for improved accessibility will influence the market dynamics moving forward. The innovation and the successful commercialization of new treatments will shape its trajectory in the coming years.
Impact
Recent Developments
The following are the drivers for the global chronic hepatitis B market:
Product/Innovation Strategy: Product launches and innovations in the global chronic hepatitis B market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Brii Biosciences Limited and Precision Biosciences, have been involved in the development of therapies for chronic hepatitis B.
Competitive Strategy: Enterprises led by market leaders in the global chronic hepatitis B market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.
Some of the prominent names established in this market are:
This report will be delivered in 7-10 working days.Market Lifecycle Stage
The global chronic hepatitis B market is currently in the growth stage, driven by significant advancements in the diagnosis and treatment of the disease. The market is evolving as new therapeutic options, such as gene-editing technologies and immune modulation therapies, move closer to regulatory approval. As clinical trials for these advanced therapies progress, they present an opportunity for market expansion and disruption. These emerging therapies are expected to drive the growth of the market. However, challenges such as high treatment costs and the need for improved accessibility will influence the market dynamics moving forward. The innovation and the successful commercialization of new treatments will shape its trajectory in the coming years.
Impact
- Increasing demand for chronic hepatitis B therapies is anticipated to support the growth of the global chronic hepatitis B market during the forecast period 2025-2035.
- The global chronic hepatitis B market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.
Recent Developments
- Regulatory Activities: In April 2025, the U.S. FDA granted fast-track status to PBGENE-HBV, Precision Biosciences’ gene-editing therapy candidate for chronic hepatitis B, which was subsequently tested in patients during a Phase 1 clinical trial.
- Funding Activities: In December 2024, AusperBio Therapeutics, Inc. announced the successful completion of a $73 million Series B financing.
The following are the drivers for the global chronic hepatitis B market:
- Rising Prevalence of Chronic Hepatitis B
- Continuous Advancements in Treatment Options
- Growing Awareness and Screening Initiatives
- Supportive Government Policies and Vaccination Programs
- High Treatment Costs
- Limited Access to Healthcare in Endemic Regions
Product/Innovation Strategy: Product launches and innovations in the global chronic hepatitis B market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Brii Biosciences Limited and Precision Biosciences, have been involved in the development of therapies for chronic hepatitis B.
Competitive Strategy: Enterprises led by market leaders in the global chronic hepatitis B market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.
Some of the prominent names established in this market are:
- Arrowhead Pharmaceuticals Inc.
- Ascletis Pharmaceuticals
- Arbutus Biopharma Corporation
- AusperBio Therapeutics, Inc.
- Gyre Therapeutics
- Brii Biosciences Limited
- Sino Biopharmaceutical Limited
- Gilead Sciences, Inc.
- GlaxoSmithKline
- Ionis Pharmaceuticals, Inc.
- Johnson & Johnson
- Precision Bioscience
- Vir Biotechnology, Inc.
- Virion Therapeutics, LLC
Executive Summary
Scope of Study
1. GLOBAL CHRONIC HEPATITIS B MARKET OVERVIEW
1.1 Industry Outlook
1.1.1 Introduction
1.1.2 Market Overview and Ecosystem
1.1.3 Epidemiological Analysis of Chronic Hepatitis B
1.1.3.1 By Region
1.1.4 Ongoing Clinical Trials
1.1.5 Market Trends
1.1.6 Regulatory Landscape / Compliance
1.1.6.1 Legal Requirement and Framework in the U.S.
1.1.6.2 Legal Requirement and Framework in the E.U.
1.1.6.3 Legal Requirement and Framework in Asia-Pacific
1.1.6.4 Legal Requirement and Framework in Rest-of-the-World
1.2 Market Dynamics
1.2.1 Impact Analysis
1.2.2 Market Drivers
1.2.3 Market Restraints
1.2.4 Market Opportunities
2. GLOBAL CHRONIC HEPATITIS B MARKET, BY REGION, $MILLION, 2023-2035
2.1 North America
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.3 Market Sizing and Forecast
2.1.3.1 North America Chronic Hepatitis B Market (by Country)
2.1.3.2 U.S.
2.1.3.3 Canada
2.2 Europe
2.2.1 Key Findings
2.2.2 Market Dynamics
2.2.3 Market Sizing and Forecast
2.2.3.1 Europe Chronic Hepatitis B Market (by Country)
2.2.3.1.1 U.K.
2.2.3.1.2 Germany
2.2.3.1.3 France
2.2.3.1.4 Italy
2.2.3.1.5 Spain
2.2.3.1.6 Rest-of-Europe
2.3 Asia-Pacific
2.3.1 Key Findings
2.3.2 Market Dynamics
2.3.3 Market Sizing and Forecast
2.3.3.1 Asia-Pacific Chronic Hepatitis B Market (by Country)
2.3.3.1.1 Japan
2.3.3.1.2 China
2.3.3.1.3 India
2.3.3.1.4 Australia
2.3.3.1.5 South Korea
2.3.3.1.6 Rest-of-Asia-Pacific
2.4 Rest-of-the-World
2.4.1 Key Findings
2.4.2 Market Dynamics
2.4.3 Market Size and Forecast
3. GLOBAL CHRONIC HEPATITIS B MARKET - COMPETITIVE BENCHMARKING AND COMPANY PROFILES
3.1 Competitive Benchmarking
3.2 Competitive Landscape
3.2.1 Key Strategies and Developments by Company
3.2.1.1 Funding Activities
3.2.1.2 Mergers and Acquisitions
3.2.1.3 Regulatory Approvals
3.2.1.4 Partnerships, Collaborations and Business Expansions
3.2.2 Key Developments Analysis
3.3 Company Profiles
3.3.1 Gilead Sciences, Inc.
3.3.1.1 Company Overview
3.3.1.2 Product Portfolio
3.3.1.3 Target Customers/End Users
3.3.1.4 Analyst View
3.3.2 GlaxoSmithKline
3.3.2.1 Company Overview
3.3.2.2 Product Portfolio
3.3.2.3 Target Customers/End Users
3.3.2.4 Analyst View
3.3.3 Ionis Pharmaceuticals, Inc.
3.3.3.1 Company Overview
3.3.3.2 Product Portfolio
3.3.3.3 Target Customers/End Users
3.3.3.4 Analyst View
3.3.4 Gyre Therapeutics
3.3.4.1 Company Overview
3.3.4.2 Product Portfolio
3.3.4.3 Target Customers/End Users
3.3.4.4 Analyst View
3.3.5 Ascletis Pharmaceuticals
3.3.5.1 Company Overview
3.3.5.2 Product Portfolio
3.3.5.3 Target Customers/End Users
3.3.5.4 Analyst View
3.3.6 Vir Biotechnology, Inc.
3.3.6.1 Company Overview
3.3.6.2 Product Portfolio
3.3.6.3 Target Customers/End Users
3.3.6.4 Analyst View
3.3.7 Brii Biosciences Limited
3.3.7.1 Company Overview
3.3.7.2 Product Portfolio
3.3.7.3 Target Customers/End Users
3.3.7.4 Analyst View
3.3.8 Arrowhead Pharmaceuticals Inc.
3.3.8.1 Company Overview
3.3.8.2 Product Portfolio
3.3.8.3 Target Customers/End Users
3.3.8.4 Analyst View
3.3.9 Johnson & Johnson
3.3.9.1 Company Overview
3.3.9.2 Product Portfolio
3.3.9.3 Target Customers/End Users
3.3.9.4 Analyst View
3.3.10 Sino Biopharmaceutical Limited
3.3.10.1 Company Overview
3.3.10.2 Product Portfolio
3.3.10.3 Target Customers/End Users
3.3.10.4 Analyst View
3.3.11 Arbutus Biopharma Corporation
3.3.11.1 Company Overview
3.3.11.2 Product Portfolio
3.3.11.3 Target Customers/End Users
3.3.11.4 Analyst View
3.3.12 Virion Therapeutics, LLC
3.3.12.1 Company Overview
3.3.12.2 Product Portfolio
3.3.12.3 Target Customers/End Users
3.3.12.4 Analyst View
3.3.13 AusperBio Therapeutics, Inc.
3.3.13.1 Company Overview
3.3.13.2 Product Portfolio
3.3.13.3 Target Customers/End Users
3.3.13.4 Analyst View
3.3.14 Precision Bioscience
3.3.14.1 Company Overview
3.3.14.2 Product Portfolio
3.3.14.3 Target Customers/End Users
3.3.14.4 Analyst View
4. RESEARCH METHODOLOGY
Scope of Study
1. GLOBAL CHRONIC HEPATITIS B MARKET OVERVIEW
1.1 Industry Outlook
1.1.1 Introduction
1.1.2 Market Overview and Ecosystem
1.1.3 Epidemiological Analysis of Chronic Hepatitis B
1.1.3.1 By Region
1.1.4 Ongoing Clinical Trials
1.1.5 Market Trends
1.1.6 Regulatory Landscape / Compliance
1.1.6.1 Legal Requirement and Framework in the U.S.
1.1.6.2 Legal Requirement and Framework in the E.U.
1.1.6.3 Legal Requirement and Framework in Asia-Pacific
1.1.6.4 Legal Requirement and Framework in Rest-of-the-World
1.2 Market Dynamics
1.2.1 Impact Analysis
1.2.2 Market Drivers
1.2.3 Market Restraints
1.2.4 Market Opportunities
2. GLOBAL CHRONIC HEPATITIS B MARKET, BY REGION, $MILLION, 2023-2035
2.1 North America
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.3 Market Sizing and Forecast
2.1.3.1 North America Chronic Hepatitis B Market (by Country)
2.1.3.2 U.S.
2.1.3.3 Canada
2.2 Europe
2.2.1 Key Findings
2.2.2 Market Dynamics
2.2.3 Market Sizing and Forecast
2.2.3.1 Europe Chronic Hepatitis B Market (by Country)
2.2.3.1.1 U.K.
2.2.3.1.2 Germany
2.2.3.1.3 France
2.2.3.1.4 Italy
2.2.3.1.5 Spain
2.2.3.1.6 Rest-of-Europe
2.3 Asia-Pacific
2.3.1 Key Findings
2.3.2 Market Dynamics
2.3.3 Market Sizing and Forecast
2.3.3.1 Asia-Pacific Chronic Hepatitis B Market (by Country)
2.3.3.1.1 Japan
2.3.3.1.2 China
2.3.3.1.3 India
2.3.3.1.4 Australia
2.3.3.1.5 South Korea
2.3.3.1.6 Rest-of-Asia-Pacific
2.4 Rest-of-the-World
2.4.1 Key Findings
2.4.2 Market Dynamics
2.4.3 Market Size and Forecast
3. GLOBAL CHRONIC HEPATITIS B MARKET - COMPETITIVE BENCHMARKING AND COMPANY PROFILES
3.1 Competitive Benchmarking
3.2 Competitive Landscape
3.2.1 Key Strategies and Developments by Company
3.2.1.1 Funding Activities
3.2.1.2 Mergers and Acquisitions
3.2.1.3 Regulatory Approvals
3.2.1.4 Partnerships, Collaborations and Business Expansions
3.2.2 Key Developments Analysis
3.3 Company Profiles
3.3.1 Gilead Sciences, Inc.
3.3.1.1 Company Overview
3.3.1.2 Product Portfolio
3.3.1.3 Target Customers/End Users
3.3.1.4 Analyst View
3.3.2 GlaxoSmithKline
3.3.2.1 Company Overview
3.3.2.2 Product Portfolio
3.3.2.3 Target Customers/End Users
3.3.2.4 Analyst View
3.3.3 Ionis Pharmaceuticals, Inc.
3.3.3.1 Company Overview
3.3.3.2 Product Portfolio
3.3.3.3 Target Customers/End Users
3.3.3.4 Analyst View
3.3.4 Gyre Therapeutics
3.3.4.1 Company Overview
3.3.4.2 Product Portfolio
3.3.4.3 Target Customers/End Users
3.3.4.4 Analyst View
3.3.5 Ascletis Pharmaceuticals
3.3.5.1 Company Overview
3.3.5.2 Product Portfolio
3.3.5.3 Target Customers/End Users
3.3.5.4 Analyst View
3.3.6 Vir Biotechnology, Inc.
3.3.6.1 Company Overview
3.3.6.2 Product Portfolio
3.3.6.3 Target Customers/End Users
3.3.6.4 Analyst View
3.3.7 Brii Biosciences Limited
3.3.7.1 Company Overview
3.3.7.2 Product Portfolio
3.3.7.3 Target Customers/End Users
3.3.7.4 Analyst View
3.3.8 Arrowhead Pharmaceuticals Inc.
3.3.8.1 Company Overview
3.3.8.2 Product Portfolio
3.3.8.3 Target Customers/End Users
3.3.8.4 Analyst View
3.3.9 Johnson & Johnson
3.3.9.1 Company Overview
3.3.9.2 Product Portfolio
3.3.9.3 Target Customers/End Users
3.3.9.4 Analyst View
3.3.10 Sino Biopharmaceutical Limited
3.3.10.1 Company Overview
3.3.10.2 Product Portfolio
3.3.10.3 Target Customers/End Users
3.3.10.4 Analyst View
3.3.11 Arbutus Biopharma Corporation
3.3.11.1 Company Overview
3.3.11.2 Product Portfolio
3.3.11.3 Target Customers/End Users
3.3.11.4 Analyst View
3.3.12 Virion Therapeutics, LLC
3.3.12.1 Company Overview
3.3.12.2 Product Portfolio
3.3.12.3 Target Customers/End Users
3.3.12.4 Analyst View
3.3.13 AusperBio Therapeutics, Inc.
3.3.13.1 Company Overview
3.3.13.2 Product Portfolio
3.3.13.3 Target Customers/End Users
3.3.13.4 Analyst View
3.3.14 Precision Bioscience
3.3.14.1 Company Overview
3.3.14.2 Product Portfolio
3.3.14.3 Target Customers/End Users
3.3.14.4 Analyst View
4. RESEARCH METHODOLOGY
LIST OF FIGURES
Figure: Global Chronic Hepatitis B Market, Market Overview
Figure: Global Chronic Hepatitis B Market, Epidemiological Analysis, U.S.
Figure: Global Chronic Hepatitis B Market, Epidemiological Analysis, EU5
Figure: Global Chronic Hepatitis B Market, Epidemiological Analysis, Rest-of-the-World
Figure: Global Chronic Hepatitis B Market Coverage
Figure: Global Chronic Hepatitis B Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Chronic Hepatitis B Market, Competitive Landscape, January 2022-April 2025
Figure: Global Chronic Hepatitis B Market, Market Overview
Figure: Global Chronic Hepatitis B Market, Epidemiological Analysis, U.S.
Figure: Global Chronic Hepatitis B Market, Epidemiological Analysis, EU5
Figure: Global Chronic Hepatitis B Market, Epidemiological Analysis, Rest-of-the-World
Figure: Global Chronic Hepatitis B Market Coverage
Figure: Global Chronic Hepatitis B Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Chronic Hepatitis B Market, Competitive Landscape, January 2022-April 2025
LIST OF TABLES
Table: Global Chronic Hepatitis B Market, Regulatory Scenario
Table: Global Chronic Hepatitis B Market Dynamics, Impact Analysis
Table: Global Chronic Hepatitis B Market, Regulatory Scenario
Table: Global Chronic Hepatitis B Market Dynamics, Impact Analysis
